Raja Mohiuddin, MD
Gastroenterology · Greenbelt, MDNPI 1992887335
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gastroenterology clinicians in MD, where the typical reported total is $2,763.
Across 175 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$578
- Johnson & Johnson$398
- AbbVie$306
- Ferring Pharmaceuticals Inc.$252
- Takeda Pharmaceuticals U.S.A., Inc.$252
- Pfizer$186
- plus $969 from 18 others
Across 79 payments — averaging $4809.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$298K
- GSK$51K
- Bausch Health US, LLC$20K
- Caris MPI, Inc.$5K
- Madrigal Pharmaceuticals$3K
- Amgen$3K
What the payments were for
- Consulting fees$261%
- Food & beverage$2,76294%
- Education$973%
- Gifts$562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $578 |
| Johnson & Johnson | 23 | $398 |
| AbbVie(2 entities) | 17 | $306 |
| Ferring Pharmaceuticals Inc. | 16 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $252 |
| Pfizer | 9 | $186 |
| Gilead | 8 | $139 |
| Braintree Laboratories, Inc. | 5 | $105 |
| Ardelyx, Inc. | 3 | $102 |
| Redhill Biopharma Inc. | 4 | $87 |
| Merck | 5 | $83 |
| Phathom Pharmaceuticals, Inc. | 5 | $79 |
| Endo Pharmaceuticals Inc. | 4 | $61 |
| Bristol Myers Squibb | 3 | $50 |
| Madrigal Pharmaceuticals | 1 | $46 |
| Evoke Pharma, Inc. | 3 | $43 |
| Intercept Pharmaceuticals, Inc. | 2 | $42 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $24 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sanofi | 1 | $16 |
| Capsovision, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| QOL Medical, LLC | 1 | $13 |
How this compares
$2,941 in reported general payments places this provider in the 50th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 44 | $43,069 |
| ViberziEluxadoline | 23 | $39,697 |
| Mesalamine | 32 | $15,224 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 259 | $14,644 |
| Dexlansoprazole DrDexlansoprazole | 36 | $13,079 |
| Mesalamine DrMesalamine | 11 | $4,169 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 19 | $3,300 |
| Omeprazole | 212 | $3,287 |
| Mesalamine ErMesalamine | 17 | $2,870 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 19 | $2,678 |
| Pantoprazole Sodium | 107 | $1,642 |
| Sucralfate | 14 | $1,065 |
| Famotidine | 52 | $628 |
| Dicyclomine Hcl | 21 | $547 |
| Ondansetron OdtOndansetron | 16 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Viberzi | $306 | $82,76667 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $252 | $3,30019 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $578 | $2,67819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Greenbelt
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Zachary BormanChevy Chase$520K
- Mouen KhashabBaltimore$440K
- Erica CohenChevy Chase$385K
- Natarajan RavendhranCatonsville$367K
- Raymond CrossBaltimore$341K
- Raja TaunkAnnapolis$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.